CY1113559T1 - Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης - Google Patents

Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης

Info

Publication number
CY1113559T1
CY1113559T1 CY20131100080T CY131100080T CY1113559T1 CY 1113559 T1 CY1113559 T1 CY 1113559T1 CY 20131100080 T CY20131100080 T CY 20131100080T CY 131100080 T CY131100080 T CY 131100080T CY 1113559 T1 CY1113559 T1 CY 1113559T1
Authority
CY
Cyprus
Prior art keywords
compounds
serotonin receptor
azepine derivatives
receptor regulators
serotonin
Prior art date
Application number
CY20131100080T
Other languages
English (en)
Inventor
Youssef L Bennani
Michael J Robarge
David C Bom
Norbert Varga
Lawrence N Tumey
Original Assignee
Athersys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys, Inc. filed Critical Athersys, Inc.
Publication of CY1113559T1 publication Critical patent/CY1113559T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση γενικά σχετίζεται με μία σειρά ενώσεων, με φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις, και με ενώσεις και συνθέσεις για χρήση ως θεραπευτικά μέσα. Ειδικότερα, οι ενώσεις της παρούσας εφεύρεσης είναι ενώσεις εξαϋδροαζεπινοϊνδόλης και οκταϋδροαζεπινοϊνδόλης. Αυτές οι ενώσεις είναι συνδέτες υποδοχέων σεροτονίνης (5-ΗΤ) και χρησιμεύουν στην αντιμετώπιση νόσων, διαταραχών και καταστάσεων όπου επιθυμείται η ρύθμιση των υποδοχέων σεροτονίνης (5-ΗΤ) (π.χ. άγχος, κατάθλιψη και παχυσαρκία).
CY20131100080T 2004-06-30 2013-01-30 Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης CY1113559T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58491604P 2004-06-30 2004-06-30
EP05789932A EP1778243B1 (en) 2004-06-30 2005-06-29 Substituted azepine derivatives as serotonin receptor modulators

Publications (1)

Publication Number Publication Date
CY1113559T1 true CY1113559T1 (el) 2016-06-22

Family

ID=35783355

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100080T CY1113559T1 (el) 2004-06-30 2013-01-30 Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης

Country Status (21)

Country Link
US (2) US7718647B2 (el)
EP (1) EP1778243B1 (el)
JP (1) JP5025469B2 (el)
KR (1) KR101216984B1 (el)
CN (1) CN1980710B (el)
AR (1) AR049954A1 (el)
AU (1) AU2005260636B2 (el)
BR (1) BRPI0512742A (el)
CA (1) CA2565683C (el)
CY (1) CY1113559T1 (el)
DK (1) DK1778243T3 (el)
ES (1) ES2398694T3 (el)
IL (1) IL179278A (el)
NO (1) NO20070494L (el)
NZ (1) NZ550891A (el)
RU (1) RU2485125C2 (el)
SI (1) SI1778243T1 (el)
TW (1) TWI358410B (el)
UA (1) UA88786C2 (el)
WO (1) WO2006004931A2 (el)
ZA (1) ZA200609234B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101404882A (zh) * 2006-01-19 2009-04-08 阿特西斯公司 作为5-羟色胺5-HT2c受体配体的噻吩基和吡咯基氮杂类及其用途
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
US8147315B2 (en) 2006-09-12 2012-04-03 Aristocrat Technologies Australia Ltd Gaming apparatus with persistent game attributes
CA2682377A1 (en) * 2007-03-30 2008-10-09 Nippon Shinyaku Co., Ltd. Heteroaryl derivatives
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
JP5996528B2 (ja) * 2010-05-21 2016-09-21 アッヴィ・インコーポレイテッド ５−ｈｔ受容体調節物質およびその使用方法
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
CN105101967B (zh) 2012-12-21 2019-06-28 雅培控股公司 作为血清素5-ht2c受体配体的苯并吖庚因及其应用
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
DE102013208337A1 (de) * 2013-05-07 2014-11-13 Henkel Ag & Co. Kgaa Aerosolzusammensetzung mit verbesserten Sprüheigenschaften
KR101917264B1 (ko) * 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
ZA821020B (en) * 1981-02-18 1983-10-26 Thomae Gmbh Dr K Azepine derivatives, process for their preparation and pharmaceutical compositions thereof
DE3230696A1 (de) * 1982-08-18 1984-02-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue thieno-thiazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8800891D0 (en) 1988-01-15 1988-02-17 Lilly Industries Ltd Pharmaceutical compounds
GB9025890D0 (en) * 1990-11-28 1991-01-09 Lilly Industries Ltd Pharmaceutical compounds
KR100196563B1 (ko) * 1993-03-17 1999-06-15 기따사또 이찌로 혈소판 응집 저해작용을 갖는 신규한 화합물
AU3619795A (en) * 1994-10-11 1996-05-02 Takeda Chemical Industries Ltd. Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors
JPH1165082A (ja) * 1997-08-11 1999-03-05 Fujitsu Ltd フォトマスク及び半導体装置の製造方法
US6369222B1 (en) * 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
US6583135B2 (en) 2000-09-20 2003-06-24 Pharmacia & Upjohn Company Substituted azepino[4,5b]indole derivatives
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
JP2003261566A (ja) * 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
US7452911B2 (en) * 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
BRPI0414541B8 (pt) 2003-09-17 2021-05-25 Janssen Pharmaceutica Nv compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários

Also Published As

Publication number Publication date
CN1980710A (zh) 2007-06-13
BRPI0512742A (pt) 2008-04-15
SI1778243T1 (sl) 2013-03-29
US20060003990A1 (en) 2006-01-05
ZA200609234B (en) 2008-08-27
CA2565683C (en) 2013-04-02
KR101216984B1 (ko) 2013-01-02
DK1778243T3 (da) 2013-02-04
TW200611906A (en) 2006-04-16
JP2008505101A (ja) 2008-02-21
NO20070494L (no) 2007-03-23
CN1980710B (zh) 2013-06-12
EP1778243B1 (en) 2012-10-31
KR20070041544A (ko) 2007-04-18
NZ550891A (en) 2009-10-30
WO2006004931A3 (en) 2006-04-13
AU2005260636A1 (en) 2006-01-12
EP1778243A2 (en) 2007-05-02
RU2007103465A (ru) 2008-08-10
WO2006004931A2 (en) 2006-01-12
JP5025469B2 (ja) 2012-09-12
IL179278A (en) 2014-11-30
US7718647B2 (en) 2010-05-18
TWI358410B (en) 2012-02-21
UA88786C2 (ru) 2009-11-25
ES2398694T3 (es) 2013-03-21
AR049954A1 (es) 2006-09-20
US20100190772A1 (en) 2010-07-29
CA2565683A1 (en) 2006-01-12
RU2485125C2 (ru) 2013-06-20
EP1778243A4 (en) 2009-09-30
IL179278A0 (en) 2007-03-08
AU2005260636B2 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
CY1113559T1 (el) Παραγωγα υποκατεστημενης αζεπινης ως ρυθμιστες υποδοχεων σεροτονινης
CY1118096T1 (el) Ρυθμιστες υποδοχεα οπιοειδους
TW200619196A (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
NO20083481L (no) Tiofenyl- og pyrrolylazepiner som serotonin 5-HT2C-reseptorligander og anvendelser derav
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
UY28150A1 (es) Agentes terapeuticos
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
TW200621787A (en) Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
BR0311494A (pt) Novos indóis substituìdos
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
TW200800943A (en) Indane derivatives as MCH receptor antagonists
CY1112418T1 (el) Παραγωγα σουλφονυλοπυραζολινο-1-καρβοξαμιδινης ως 5-ητ6 ανταγωνιστες
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
UY28377A1 (es) Agentes terapeuticos
BRPI0516749A (pt) composições e métodos para tratamento de disturbìos cognitivos
MX2010001195A (es) Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3.
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
ATE498619T1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.